
Diabetes Dialogue: Prescribing Tirzepatide, Biosimilar Insulins, and Misdiagnosis of T1D
In this episode, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss their experiences with prescribing tirzepatide (Mounjaro) and what issues patients have encountered, the prospect of new biosimilar insulins that may be coming to the market, and the misdiagnosis of type 1 diabetes in adult patients.
When looking back, June 2022 will be remembered as a whirlwind month for the diabetes community. With Eli Lilly and Company announcing their novel dual GIP/GLP-1 receptor agonist
With hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, recording 4 episodes at
Diabetes Dialogue: Therapeutics, Technology, and Real-World Perspectives is available in an audio-only format on










































































